Cargando…

Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review

OBJECTIVES: This review aimed to summarise the existing knowledge about placebo and nocebo effects associated with pharmacological interventions and their mechanisms. DESIGN: Umbrella review, adopting the Assessment of Multiple Systematic Reviews 2 tool for critical appraisal. DATA SOURCES: MEDLINE/...

Descripción completa

Detalles Bibliográficos
Autores principales: Frisaldi, Elisa, Shaibani, Aziz, Benedetti, Fabrizio, Pagnini, Francesco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582987/
https://www.ncbi.nlm.nih.gov/pubmed/37848293
http://dx.doi.org/10.1136/bmjopen-2023-077243
_version_ 1785122460730916864
author Frisaldi, Elisa
Shaibani, Aziz
Benedetti, Fabrizio
Pagnini, Francesco
author_facet Frisaldi, Elisa
Shaibani, Aziz
Benedetti, Fabrizio
Pagnini, Francesco
author_sort Frisaldi, Elisa
collection PubMed
description OBJECTIVES: This review aimed to summarise the existing knowledge about placebo and nocebo effects associated with pharmacological interventions and their mechanisms. DESIGN: Umbrella review, adopting the Assessment of Multiple Systematic Reviews 2 tool for critical appraisal. DATA SOURCES: MEDLINE/PubMed, Scopus, Web of Science, PsycINFO, Cochrane Central Register of Controlled Trial were searched in September 2022, without any time restriction, for systematic reviews, narrative reviews, original articles. Results were summarised through narrative synthesis, tables, 95% CI. OUTCOME MEASURES: Mechanisms underlying placebo/nocebo effects and/or their effect sizes. RESULTS: The databases search identified 372 studies, for a total of 158 312 participants, comprising 41 systematic reviews, 312 narrative reviews and 19 original articles. Seventy-three per cent of the examined systematic reviews were of high quality. Our findings revealed that mechanisms underlying placebo and/or nocebo effects have been characterised, at least in part, for: pain, non-noxious somatic sensation, Parkinson’s disease, migraine, sleep disorders, intellectual disability, depression, anxiety, dementia, addiction, gynaecological disorders, attention-deficit hyperactivity disorder, immune and endocrine systems, cardiovascular and respiratory systems, gastrointestinal disorders, skin diseases, influenza and related vaccines, oncology, obesity, physical and cognitive performance. Their magnitude ranged from 0.08 to 2.01 (95% CI 0.37 to 0.89) for placebo effects and from 0.32 to 0.90 (95% CI 0.24 to 1.00) for nocebo effects. CONCLUSIONS: This study provides a valuable tool for clinicians and researchers, identifying both results ready for clinical practice and gaps to address in the near future. FUNDING: Università Cattolica del Sacro Cuore, Milan, Italy with the ‘Finanziamento Ponte 2022’ grant. PROSPERO REGISTRATION NUMBER: CRD42023392281.
format Online
Article
Text
id pubmed-10582987
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BMJ Publishing Group
record_format MEDLINE/PubMed
spelling pubmed-105829872023-10-19 Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review Frisaldi, Elisa Shaibani, Aziz Benedetti, Fabrizio Pagnini, Francesco BMJ Open Pharmacology and Therapeutics OBJECTIVES: This review aimed to summarise the existing knowledge about placebo and nocebo effects associated with pharmacological interventions and their mechanisms. DESIGN: Umbrella review, adopting the Assessment of Multiple Systematic Reviews 2 tool for critical appraisal. DATA SOURCES: MEDLINE/PubMed, Scopus, Web of Science, PsycINFO, Cochrane Central Register of Controlled Trial were searched in September 2022, without any time restriction, for systematic reviews, narrative reviews, original articles. Results were summarised through narrative synthesis, tables, 95% CI. OUTCOME MEASURES: Mechanisms underlying placebo/nocebo effects and/or their effect sizes. RESULTS: The databases search identified 372 studies, for a total of 158 312 participants, comprising 41 systematic reviews, 312 narrative reviews and 19 original articles. Seventy-three per cent of the examined systematic reviews were of high quality. Our findings revealed that mechanisms underlying placebo and/or nocebo effects have been characterised, at least in part, for: pain, non-noxious somatic sensation, Parkinson’s disease, migraine, sleep disorders, intellectual disability, depression, anxiety, dementia, addiction, gynaecological disorders, attention-deficit hyperactivity disorder, immune and endocrine systems, cardiovascular and respiratory systems, gastrointestinal disorders, skin diseases, influenza and related vaccines, oncology, obesity, physical and cognitive performance. Their magnitude ranged from 0.08 to 2.01 (95% CI 0.37 to 0.89) for placebo effects and from 0.32 to 0.90 (95% CI 0.24 to 1.00) for nocebo effects. CONCLUSIONS: This study provides a valuable tool for clinicians and researchers, identifying both results ready for clinical practice and gaps to address in the near future. FUNDING: Università Cattolica del Sacro Cuore, Milan, Italy with the ‘Finanziamento Ponte 2022’ grant. PROSPERO REGISTRATION NUMBER: CRD42023392281. BMJ Publishing Group 2023-10-17 /pmc/articles/PMC10582987/ /pubmed/37848293 http://dx.doi.org/10.1136/bmjopen-2023-077243 Text en © Author(s) (or their employer(s)) 2023. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. https://creativecommons.org/licenses/by-nc/4.0/This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) .
spellingShingle Pharmacology and Therapeutics
Frisaldi, Elisa
Shaibani, Aziz
Benedetti, Fabrizio
Pagnini, Francesco
Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
title Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
title_full Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
title_fullStr Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
title_full_unstemmed Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
title_short Placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
title_sort placebo and nocebo effects and mechanisms associated with pharmacological interventions: an umbrella review
topic Pharmacology and Therapeutics
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10582987/
https://www.ncbi.nlm.nih.gov/pubmed/37848293
http://dx.doi.org/10.1136/bmjopen-2023-077243
work_keys_str_mv AT frisaldielisa placeboandnoceboeffectsandmechanismsassociatedwithpharmacologicalinterventionsanumbrellareview
AT shaibaniaziz placeboandnoceboeffectsandmechanismsassociatedwithpharmacologicalinterventionsanumbrellareview
AT benedettifabrizio placeboandnoceboeffectsandmechanismsassociatedwithpharmacologicalinterventionsanumbrellareview
AT pagninifrancesco placeboandnoceboeffectsandmechanismsassociatedwithpharmacologicalinterventionsanumbrellareview